Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate
• Rising prostate-specific antigen AND radiographic evidence of extraprostatic prostate cancer by bone scan, CT scan, prostascint scan, or MRI
• PATIENT CHARACTERISTICS:
• Age
• 40 and over
• Performance status
• Karnofsky 80-100%
• Life expectancy
• Not specified
• Hematopoietic
• WBC greater than 4,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hemoglobin greater than 10.0 g/dL
• Hepatic
• Bilirubin normal
• AST normal
• Alkaline phosphatase normal
• No acute or chronic liver disease
• Renal
• Creatinine less than 1.5 times upper limit of normal
• Cardiovascular
• Ejection fraction at least 50% by MUGA
• EKG normal
• No myocardial infarction or cerebral vascular accident within the past 6 months
• No life threatening cardiac arrhythmias
• No congestive heart failure
• No cardiac pacemaker
• No peripheral arterial disease with intermittent claudication or Leriches syndrome (i.e., claudication of the buttocks or perineum)
• Other
• Fertile patients must use effective barrier contraception during and for 3 months after study participation
• No sperm donation during and for 3 months after study participation
• Not febrile
• No interest in future fertility or fathering children
• No significantly decreased pain response
• No severe urethral stricture
• No protruding median lobe resulting in a "ball-valve" type of obstruction at the bladder neck
• No major psychiatric illness that would prevent informed consent
• No major psychiatric illness that required inpatient treatment within the past 3 months
• No psychological, family, sociological, or geographic condition that would preclude study compliance
• No allergy to eggs or egg products
• No urinary or prostatic infection
• No full urinary retention
• No penile or urinary sphincter implant
• No metallic implants in the pelvic or femoral area
• No other serious medical illness that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent live vaccines
• Chemotherapy
• No prior anthracycline
• No concurrent streptozocin
• Endocrine therapy
• No concurrent hormonal therapy (except luteinizing hormone-releasing hormone analog)
• No concurrent glucocorticoids administered at more than physiologic replacement doses (other than as an antiemetic)
• Radiotherapy
• Not specified
• Surgery
• More than 3 months since prior major surgery
• Other
• No prior therapy that resulted in permanent reduction of pain response (e.g., prior surgery, regional or local anesthetic)
• No concurrent PC-SPES
• No concurrent cyclosporine, phenobarbital, or phenytoin